Jefferies Discusses Elan Corp (ELN) After 2012 Global Healthcare Conference

Jefferies commented on Elan Corp (NYSE: ELN) following the Jefferies 2012 Global Healthcare Conference, where CEO Kelly Martin presented.

The firm comments, "Investor interest in ELN is at an all time high with the imminent bapineuzumab Ph.3 Alzheimer's data -- one of the most important data events in the entire industry. ELN can't comment on Bapi, but reiterated its confidence in Tysabri growth (easily a >$3B product w/ 20% market share). Thus we continue to believe Bapi is upside to the valuation."

The firm maintained their Buy rating and price target of $20.00

For an analyst ratings summary and ratings history on Elan Corp click here. For more ratings news on Elan Corp click here.

Shares of Elan Corp closed at $13.43 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential